Dana-Farber Leads Phase 3 Trials for Breast, Lung, and Bladder Cancer Unveiled at ESMO Congress 2025
Dana-Farber Cancer Institute’s groundbreaking research continues to shape the landscape of oncology as their experts present a series of pivotal ...
Tag: EGFR-mutated NSCLC treatment
PALOMA-2 Study Reveals High Response Rates with Monthly Subcutaneous Amivantamab Combined with Lazertinib in EGFR-Mutated NSCLC
In a significant advancement for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) ...
FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC
In a groundbreaking advancement within the realm of targeted oncology, the international cancer research community has witnessed compelling evidence supporting ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!